Search Results

The forecast makes pharma one of the fastest-growing manufacturing industries in the U.S.

WeGuide Pty Ltd will receive A$1.9 million to build a world first platform in developing commercial multi-modal biomarkers. Building their first use case with NeuRA on mobility recovery, the platform accelerates regulatory-approved biomarker development for researchers, health organisations and pharmaceutical companies working to bring precision medicine tools to patients and trial participants.

The FDA will convene its vaccines advisory panel to discuss seasonal COVID-19 vaccines—a surprise move after Health Secretary and vaccine skeptic Robert F. Kennedy, Jr. overhauled a separate vaccine committee.

For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding the expression of disease-causing proteins.

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment challenges.

Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to treat severe swelling episodes caused by the rare genetic disorder hereditary angioedema.